Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company"s lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.
Website: unither.com



Growth: Pretty weak revenue growth rate 6.8%, there is slowdown compared to average historical growth rates 19.2%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +50.1%. On average the margin is improving unsteadily. Gross margin is high, +87.4%. In the last quarter the company beat the estimated EPS, +7.5%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.1 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 149.5% higher than minimum and 9.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.7x by EV / Sales multiple , the company can be 34.2% overvalued

Insiders: For the last 3 months insiders sold company shares on $430.8 mln (-1.711% of cap.)

Key Financials (Download financials)

Ticker: UTHR
Share price, USD:  (+0.2%)525.82
year average price 468.76  


year start price 294.28 2025-08-01

min close price 292.65 2025-08-04

max close price 578.17 2026-05-26

current price 525.82 2026-07-31
Common stocks: 45 500 000

Dividend Yield:  0.0%
FCF Yield LTM: 0.8%
EV / LTM EBITDA: 14.4x
EV / EBITDA annualized: 13.7x
Last revenue growth (y/y):  +6.8%
Last growth of EBITDA (y/y):  +13.3%
Historical revenue growth:  +19.2%
Historical growth of EBITDA:  +16.8%
EV / Sales: 7.2x
Margin (EBITDA LTM / Revenue): 50.1%
Fundamental value created in LTM:
Market Cap ($m): 23 874
Net Debt ($m): -1 340
EV (Enterprise Value): 22 534
Price to Book: 3.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-22businesswire.com

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

2026-01-13seekingalpha.com

United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-11zacks.com

Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock

2025-11-04zacks.com

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

2025-10-29zacks.com

United Therapeutics (UTHR) Beats Q3 Earnings Estimates

2025-10-01zacks.com

Is IPF the Next Big Market Opportunity for United Therapeutics?

2025-09-28seekingalpha.com

United Therapeutics Corporation - Special Call

2025-09-03forbes.com

United Therapeutics: Is UTHR Stock Still A Buy At $400?

2025-09-02proactiveinvestors.com

United Therapeutics shares jump on positive lung disease study results

2025-08-27seekingalpha.com

United Therapeutics: Critical September IPF Data Catalyst Sets Up Momentous Year
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-05-01 2023-11-01 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-10-29 06:32:18 2025-07-30 06:34:20 2025-02-26 06:33:08 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26 2022-02-24 06:05:01 2021-02-24 06:07:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 800M 799M 2 877M 749M 715M 678M 2 328M 609M 597M 507M 1 936M 516M 1 686M 1 483M
costOfRevenue 101M 88M 310M 83M 78M 73M 258M 70M 64M 52M 147M 37M 123M 108M
grossProfit 699M 711M 2 568M 666M 637M 605M 2 070M 539M 532M 455M 1 790M 479M 1 563M 1 375M
grossProfitRatio 0.874 0.89 0.889 0.891 0.892 0.885 0.893 0.897 0.928
researchAndDevelopmentExpenses 128M 134M 481M 104M 140M 104M 408M 85M 89M 83M 323M 66M 540M 358M
generalAndAdministrativeExpenses 0 160M 542M 199M 152M 121M 395M 107M 110M 70M 416M 81M 403M 369M
sellingAndMarketingExpenses 0 31M 96M 21M 25M 23M 82M 21M 20M 17M 71M 17M 64M 55M
sellingGeneralAndAdministrativeExpenses 183M 191M 639M 219M 178M 144M 477M 128M 130M 87M 487M 98M 467M 424M
otherExpenses 0 22M 71M 0 800 000 2M 0 -5M -600 000 -8M 0 0 0 0
operatingExpenses 310M 347M 1 191M 323M 317M 249M 885M 212M 219M 170M 810M 165M 1 007M 782M
costAndExpenses 411M 434M 1 500M 406M 395M 321M 1 143M 282M 283M 223M 957M 202M 1 130M 890M
interestIncome 46M 51M 199M 50M 46M 54M 163M 45M 37M 29M 45M 13M 17M 29M
interestExpense 3M 7M 43M 10M 12M 13M 59M 16M 15M 14M 32M 9M 19M 24M
depreciationAndAmortization 22M 21M 73M 19M 19M 15M 53M 40M 37M 35M 51M 20M 50M 50M
ebitda 463M 437M 1 654M 418M 339M 427M 1 387M 367M 350M 319M 1 040M 335M 737M 646M
ebitdaratio 0.579 0.547 0.558 0.474 0.63 0.603 0.587 0.629 0.648
operatingIncome 389M 365M 1 377M 343M 320M 356M 1 185M 327M 313M 284M 980M 314M 556M 594M
operatingIncomeRatio 0.486 0.456 0.458 0.447 0.526 0.537 0.525 0.561 0.609
totalOtherIncomeExpensesNet 50M 44M 162M 46M 35M 2M 89M -5M -600 000 8M -29M -2M 38M 45M
incomeBeforeTax 438M 408M 1 539M 389M 355M 399M 1 274M 352M 335M 292M 951M 313M 594M 639M
incomeBeforeTaxRatio 0.548 0.511 0.519 0.497 0.588 0.577 0.562 0.576 0.606
incomeTaxExpense 99M 99M 344M 80M 77M 92M 290M 84M 76M 51M 223M 73M 118M 124M
netIncome 339M 310M 1 195M 309M 278M 307M 985M 268M 259M 241M 727M 239M 476M 515M
netIncomeRatio 0.424 0.388 0.413 0.389 0.452 0.439 0.435 0.475 0.464
eps 7.73 6.86 26.44 6.93 6.26 6.52 21.04 5.71 5.53 5.2 15.98 5.26 10.6 11.65
epsdiluted 7.16 6.41 6.39 5.85 6.17 5.38 5.24 4.86 4.91
weightedAverageShsOut 44M 45M 45M 45M 44M 47M 47M 47M 47M 46M 46M 46M 45M 44M
weightedAverageShsOutDil 47M 48M 49M 48M 48M 50M 50M 50M 50M 50M 49M 49M 47M 45M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-21 2023-02-22 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 156M 103M 13M -2M 5M
ebit 1 582M 1 334M 989M 687M 596M
nonOperatingIncomeExcludingInterest -205M -149M -9M -131M -3M
netIncomeFromContinuingOperations 1 195M 985M 727M 476M 515M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 1 195M 985M 727M 476M 515M
epsDiluted 24.64 19.81 15 10.06 11.54

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-05-01 2023-11-01 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-10-29 06:32:18 2025-07-30 06:34:20 2025-02-26 06:33:08 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26 2022-02-24 06:05:01 2021-02-24 06:07:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 137M 1 593M 1 697M 1 554M 1 356M 1 252M 1 208M 1 108M 1 067M 1 164M 961M 967M 895M 739M
shortTermInvestments 1 631M 1 456M 1 570M 1 773M 1 616M 1 456M 1 786M 3 829M 3 635M 1 700M 1 878M 1 649M 1 036M 1 096M
cashAndShortTermInvestments 2 768M 3 049M 3 267M 3 327M 2 972M 2 708M 2 994M 4 936M 4 703M 2 863M 2 839M 2 616M 1 931M 1 835M
netReceivables 298M 379M 279M 342M 291M 307M 279M 259M 273M 135M 220M 232M 199M 157M
inventory 177M 169M 158M 147M 137M 120M 112M 104M 103M 103M 102M 91M 94M 87M
otherCurrentAssets 252M 230M 170M 185M 221M 113M 166M 1 988M 1 770M 93M 219M 118M 100M 88M
totalCurrentAssets 3 494M 3 827M 3 874M 4 000M 3 620M 3 249M 3 551M 3 459M 3 213M 3 193M 3 380M 3 056M 2 324M 2 167M
propertyPlantEquipmentNet 1 556M 1 362M 1 222M 1 157M 1 095M 1 074M 1 045M 992M 939M 897M 862M 841M 781M 732M
goodwill 0 0 32M 0 0 0 34M 0 0 0 28M 28M 28M 28M
intangibleAssets 117M 112M 80M 112M 115M 115M 81M 44M 0 0 17M 17M 17M 130M
goodwillAndIntangibleAssets 117M 112M 112M 112M 115M 115M 114M 44M 45M 45M 45M 45M 45M 158M
longTermInvestments 1 656M 1 918M 1 475M 1 279M 1 359M 1 492M 1 910M 2 061M 2 024M 1 766M 1 316M 1 444M 1 650M 1 150M
taxAssets 355M 456M 458M 391M 396M 396M 395M 326M 326M 322M 328M 281M 262M 239M
otherNonCurrentAssets 174M 233M 222M 184M 139M 169M 152M 142M 135M 125M 114M 115M 108M 170M
totalNonCurrentAssets 3 857M 4 081M 3 490M 3 123M 3 104M 3 247M 3 616M 3 565M 3 468M 3 153M 2 664M 2 725M 2 846M 2 448M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 7 351M 7 908M 7 364M 7 123M 6 723M 6 495M 7 167M 7 024M 6 681M 6 346M 6 045M 5 782M 5 169M 4 615M
accountPayables 468M 432M 6M 364M 325M 305M 6M 333M 0 0 4M 0 4M 4M
shortTermDebt 0 0 300M 400M 400M 400M 400M 300M 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 -305M 0 -333M 0 0 0 0 0 0
otherCurrentLiabilities 78M 95M 432M 110M 107M 461M 41M 444M 370M 325M 13M 316M 248M 20M
totalCurrentLiabilities 546M 527M 738M 873M 832M 861M 804M 744M 370M 325M 343M 316M 305M 323M
longTermDebt 0 0 0 0 100M 200M 300M 500M 800M 800M 800M 800M 800M 800M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 215M 207M 182M 149M 94M 97M 78M 67M 100M 98M 105M 904M 105M 97M
totalNonCurrentLiabilities 215M 207M 182M 149M 194M 297M 378M 567M 900M 898M 905M 904M 905M 897M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 761M 734M 920M 1 022M 1 026M 1 157M 1 182M 1 312M 1 270M 1 223M 1 248M 1 219M 1 210M 1 220M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 800 000 800 000 800 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000
retainedEarnings 8 193M 7 854M 7 222M 6 921M 6 612M 6 334M 6 027M 5 810M 5 542M 5 283M 5 042M 4 910M 4 315M 3 839M
accumulatedOtherComprehensiveIncomeLoss 100 000 0 -3M 7M -15M -16M -13M -44M -51M -39M -56M -84M -23M -14M
othertotalStockholdersEquity -1 603M -681M -828M -900M -981M -55M -82M -122M -265M
totalStockholdersEquity 6 590M 7 174M 6 444M 6 101M 5 697M 5 338M 5 985M 5 712M 5 411M 5 123M 4 797M 4 562M 3 959M 3 395M
totalEquity 6 590M 7 174M 6 444M 6 101M 5 697M 5 338M 5 985M 5 712M 5 411M 5 123M 4 797M 4 562M 3 959M 3 395M
totalLiabilitiesAndStockholdersEquity 7 351M 7 908M 7 123M 6 723M 6 495M 7 024M 6 681M 6 346M 5 782M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 351M 7 908M 7 364M 7 123M 6 723M 6 495M 7 167M 7 024M 6 681M 6 346M 6 045M 5 782M 5 169M 4 615M
totalInvestments 3 287M 3 373M 3 045M 3 052M 2 975M 1 492M 3 696M 2 061M 2 024M 1 766M 3 194M 3 093M 2 686M 2 246M
totalDebt 0 0 300M 400M 500M 600M 700M 500M 800M 800M 800M 800M 800M 800M
netDebt -1 137M -1 593M -1 397M -1 154M -856M -652M -508M -608M -267M -364M -161M -167M -95M 61M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-21 2023-02-22 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 279M 279M 220M 199M 157M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 6M 6M 4M 4M 4M
otherPayables 0 0 0 0 0
accruedExpenses 0 358M 326M 54M 299M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock -3 475M -2 579M -2 579M -2 579M -2 579M
additionalPaidInCapital 2 699M 2 549M 2 388M 2 245M 2 149M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-05-01 2023-11-01 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-10-29 06:32:18 2025-07-30 06:34:20 2025-02-26 06:33:08 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26 2022-02-24 06:05:01 2021-02-24 06:07:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 339M 310M 1 195M 309M 278M 307M 985M 268M 259M 241M 727M 239M 476M 515M
depreciationAndAmortization 22M 21M 73M 19M 19M 15M 53M 13M 13M 13M 51M 13M 50M 50M
deferredIncomeTax 0 0 0 0 -4M 0 0 -3M -3M 0 0 0 0 0
stockBasedCompensation 39M 38M 144M 42M 50M 26M 39M 21M 14M -12M 107M -2M 139M 164M
changeInWorkingCapital 163M -203M -60M 13M -109M 40M -98M 11M -139M 127M -141M -7M -174M 63M
accountsReceivables 82M -57M -400 000 -51M 17M -28M -59M 14M -138M 86M -22M -58M -41M -6M
inventory -18M -7M -47M -11M -15M -9M -14M -3M -1 000 000 -3M -13M -600 000 -8M 10M
accountsPayables 31M 0 0 33M 26M 2M 0 4M 78M 3M 0 0 0 0
otherWorkingCapital 67M -138M -13M 42M -136M 76M -26M -4M -78M 41M -106M 52M -125M 59M
otherNonCashItems -100 000 26M -24M -6M 54M -11M -1M 36M -37M 6M 58M 16M 108M -36M
netCashProvidedByOperatingActivities 562M 192M 1 327M 377M 232M 377M 978M 346M 106M 375M 803M 259M 598M 756M
investmentsInPropertyPlantAndEquipment -211M -62M -247M -77M -45M -38M -230M -66M -45M -41M -139M -69M -121M -59M
acquisitionsNet 0 0 -31M 0 0 0 -89M 237M 179M 0 -2M 0 0 0
purchasesOfInvestments -416M -1 807M -1 646M -408M -231M -529M -2 514M -645M -672M -890M -1 709M -270M -1 895M -2 309M
salesMaturitiesOfInvestments 183M 1 570M 2 369M 387M 197M 1 307M 2 137M 408M 493M 710M 1 034M 246M 1 529M 1 627M
otherInvestingActivites 585M -600 000 -18M -400 000 -4M -248M -183M 0 -2M
netCashUsedForInvestingActivites 141M -300M -115M -80M 735M -313M -227M -221M -94M
debtRepayment 0 -212M -100M -100M -100M 0 0 0 0
commonStockIssued 45M 18M 0 0 4M 8M 0 61M 0
commonStockRepurchased -1 000M 0 -1 012M -400 000 -12M -1 000M -14M -200 000 0 -14M -11M -300 000 -11M -4M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -500 000 -5M 36M 64M -14M -200 000 25M 700 000 7M
netCashUsedProvidedByFinancingActivities -956M -199M -64M -48M -1 068M 8M 25M 49M 7M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 107M 0 0 0 0 0
netChangeInCash -253M -307M 490M 198M 104M 44M 247M 40M -96M 202M 66M 172M 156M 300 000
cashAtEndOfPeriod 1 340M 1 593M 1 697M 1 554M 1 356M 1 252M 1 208M 1 108M 1 067M 1 164M 961M 967M 895M 739M
cashAtBeginningOfPeriod 1 593M 1 900M 1 208M 1 356M 1 252M 1 208M 961M 1 067M 1 164M 961M 895M 795M 739M 738M
operatingCashFlow 562M 192M 1 327M 377M 232M 377M 978M 346M 106M 375M 803M 259M 598M 756M
capitalExpenditure -211M -62M -247M -77M -45M -38M -230M -66M -45M -41M -139M -69M -121M -59M
freeCashFlow 352M 130M 1 081M 301M 187M 338M 748M 281M 62M 334M 664M 190M 477M 696M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-21 2023-02-22 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -29M -23M 4M 0 2M
netCashProvidedByInvestingActivities 417M -720M -812M -487M -739M
netDebtIssuance -400M -100M 0 0 -50M
longTermNetDebtIssuance 0 -100M 0 0 -50M
shortTermNetDebtIssuance -400M 0 0 0 0
netStockIssuance -1 012M -14M -11M -11M -4M
netCommonStockIssuance -1 012M -14M -11M -11M -4M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 157M 102M 87M 56M 37M
netCashProvidedByFinancingActivities -1 255M -12M 75M 45M -17M
incomeTaxesPaid 401M 333M 276M 153M 93M
interestPaid 40M 56M 29M 16M 21M

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-04-30 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-21 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-06 10:30 ET
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
2026-04-29 11:00 ET
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
2026-04-22 11:00 ET
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
2026-04-20 ET
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
2026-04-08 ET
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
2026-03-30 ET
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
2026-03-11 ET
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
2026-03-09 ET
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
2026-03-03 ET
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
2026-03-02 ET
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
2026-02-25 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-23 ET
United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
2026-02-11 12:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
2026-01-26 ET
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
2026-01-22 ET
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
2026-01-05 ET
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-04 ET
United Therapeutics Corporation to Present at Upcoming Investor Conferences
2025-11-03 ET
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
2025-10-29 ET
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
2025-10-15 ET
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
2025-10-13 ET
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
2025-09-19 ET
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
2025-09-16 ET
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
2025-09-02 ET
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
2025-08-29 ET
United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
2025-08-01 ET
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
2025-07-30 ET
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
2025-07-16 ET
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
2025-06-24 ET
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
2025-06-23 ET
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
2025-04-30 ET
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
2025-04-21 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
2025-04-16 ET
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
2025-04-04 ET
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
2025-04-02 ET
United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
2025-03-04 ET
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
2025-02-26 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-24 ET
United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
2025-02-19 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
2025-02-04 ET
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
2025-02-03 ET
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
2025-01-21 ET
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
2025-01-06 ET
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-17 ET
United Therapeutics Announces Successful World’s First UKidney Transplant
2024-11-05 ET
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
2024-10-30 10:30 ET
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
2024-10-23 11:00 ET
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
2024-10-23 10:30 ET
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
2024-09-24 11:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
2024-09-10 11:00 ET
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
2024-08-28 11:00 ET
United Therapeutics Corporation to Present at Upcoming Investor Conferences
2024-07-31 10:30 ET
United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
2024-07-24 11:00 ET
United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
2024-07-10 11:00 ET
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
2024-06-27 11:00 ET
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
2024-06-05 11:00 ET
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-01 10:30 ET
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
2024-04-24 13:00 ET
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
2024-04-24 11:00 ET
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
2024-04-16 11:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
2024-03-26 11:00 ET
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
2024-03-25 11:00 ET
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
2024-03-25 11:00 ET
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
2024-03-05 11:00 ET
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
2024-02-27 11:00 ET
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
2024-02-21 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-21 10:55 ET
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
2024-02-14 11:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024
2023-12-29 11:00 ET
United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-07 11:00 ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024
2023-11-01 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2023 Financial Results
2023-10-31 10:05 ET
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis
2023-10-31 10:00 ET
United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023
2023-10-25 10:00 ET
United Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023
2023-09-22 18:15 ET
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs
2023-09-12 10:00 ET
United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report
2023-09-01 10:00 ET
United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-02 10:00 ET
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
2023-07-26 10:00 ET
United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023
2023-07-24 15:45 ET
United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation
2023-06-14 10:00 ET
United Therapeutics Unveils Net Zero Energy Distribution Center
2023-05-03 10:00 ET
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
2023-04-26 10:00 ET
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023
2023-04-18 10:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings
2023-03-06 21:30 ET
United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
2023-02-28 11:00 ET
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
2023-02-22 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-15 11:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023
2023-01-02 11:00 ET
United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-08 11:00 ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2023
2022-11-02 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
2022-11-01 10:00 ET
United Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare Conference
2022-10-31 10:00 ET
United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy
2022-10-26 10:00 ET
United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022
2022-10-14 10:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting
2022-10-11 10:00 ET
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis
2022-09-12 21:00 ET
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report
2022-08-31 22:40 ET
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation
2022-08-24 10:00 ET
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
2022-08-03 10:00 ET
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
2022-07-27 10:00 ET
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
2022-06-03 20:30 ET
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
2022-05-24 10:00 ET
United Therapeutics Announces FDA Approval of Tyvaso DPI™
2022-05-04 10:00 ET
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
2022-04-29 10:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
2022-04-27 10:00 ET
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
2022-04-06 10:00 ET
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
2022-03-08 11:00 ET
United Therapeutics Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference
2022-03-01 11:00 ET
United Therapeutics Corporation to Present at the Cowen 42nd Annual Health Care Conference
2022-02-24 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-21 11:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022
2022-01-21 11:00 ET
United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs
2021-12-30 11:00 ET
United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst
2021-12-03 11:00 ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
2021-11-03 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2021 Financial Results
2021-11-01 10:00 ET
United Therapeutics Corporation To Present At The Credit Suisse 30th Annual Healthcare Conference
2021-10-27 20:20 ET
Volumetric to Be Acquired by 3D Systems to Advance Tissue and Organ Manufacturing
2021-10-27 10:00 ET
United Therapeutics Corporation To Report Third Quarter 2021 Financial Results Before The Market Opens On Wednesday, November 3, 2021
2021-10-21 10:00 ET
United Therapeutics Details New Data Presented at CHEST Annual Meeting 2021
2021-10-18 10:00 ET
United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application
2021-10-11 10:00 ET
United Therapeutics to Present New Data at CHEST Annual Meeting 2021
2021-09-30 20:30 ET
United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval
2021-09-10 10:00 ET
United Therapeutics Releases its Annual Corporate Responsibility Report
2021-08-25 10:00 ET
United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month
2021-08-04 10:00 ET
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
2021-08-03 10:00 ET
United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference
2021-07-28 10:00 ET
United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021
2021-06-30 10:00 ET
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study
2021-06-07 10:00 ET
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
2021-06-03 10:00 ET
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis
2021-05-25 10:00 ET
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference
2021-05-05 10:00 ET
United Therapeutics Corporation Reports First Quarter 2021 Financial Results
2021-04-26 10:00 ET
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021
2021-04-01 10:00 ET
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
2021-03-24 10:00 ET
United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum
2021-03-09 11:00 ET
United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference
2021-02-24 21:30 ET
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference
2021-02-24 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results
2021-02-17 11:00 ET
United Therapeutics Corporation To Report Fourth Quarter And Full Year 2020 Financial Results Before The Market Opens On Wednesday, February 24, 2021
2021-02-10 11:00 ET
United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin®
2021-01-28 11:00 ET
United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective
2021-01-13 22:01 ET
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
2021-01-04 11:00 ET
United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference
2020-12-28 11:00 ET
United Therapeutics Announces Agreement To Acquire Priority Review Voucher
2020-12-09 11:00 ET
United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis
2020-11-24 11:00 ET
United Therapeutics Releases Its First Corporate Responsibility Report
2020-11-10 11:00 ET
United Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare Conference
2020-11-02 10:55 ET
United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference
2020-10-28 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2020 Financial Results
2020-10-22 10:00 ET
United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting
2020-10-21 10:00 ET
United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020
2020-10-15 10:00 ET
United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020
2020-09-21 11:00 ET
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant
2020-09-16 10:00 ET
United Therapeutics Corporation to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
2020-09-11 10:00 ET
United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors
2020-08-17 10:00 ET
United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease
2020-08-05 10:00 ET
United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference
2020-07-29 10:00 ET
United Therapeutics Corporation Reports Second Quarter 2020 Financial Results
2020-07-23 10:00 ET
United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia
2020-07-22 10:00 ET
United Therapeutics Corporation To Report Second Quarter 2020 Financial Results Before The Market Opens On Wednesday, July 29, 2020
2020-06-17 10:00 ET
United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session
2020-06-05 10:00 ET
United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents
2020-05-26 10:00 ET
United Therapeutics Corporation to Present at the Jefferies Virtual Health Care Conference
2020-05-06 10:00 ET
United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020
2020-04-29 10:00 ET
United Therapeutics Corporation Reports First Quarter 2020 Financial Results
2020-04-23 10:00 ET
United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension
2020-04-22 10:00 ET
United Therapeutics Corporation to Report First Quarter 2020 Financial Results Before the Market Opens on Wednesday, April 29, 2020
2020-02-26 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-25 11:00 ET
United Therapeutics Corporation To Present At The 40th Annual Cowen And Company Healthcare Conference
2020-02-24 11:16 ET
United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®
2020-02-24 11:00 ET
United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints
2020-02-19 11:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020
2020-02-04 22:00 ET
United Therapeutics Defeats Preliminary Injunction Motion In Litigation With Sandoz And RareGen
2020-02-03 11:00 ET
United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint
2019-10-30 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2019 Financial Results
2019-10-23 10:00 ET
United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019
2019-10-21 10:00 ET
United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study
2019-09-11 10:00 ET
United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review
2019-08-06 10:00 ET
United Therapeutics Corporation To Present At 2019 Wedbush PacGrow Healthcare Conference
2019-07-24 10:00 ET
United Therapeutics Corporation To Report Second Quarter 2019 Financial Results Before The Market Opens On Wednesday, July 31, 2019
2019-06-05 10:00 ET
United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference
2019-05-28 10:00 ET
United Therapeutics Corporation To Present at Jefferies 2019 Healthcare Conference
2019-04-29 10:00 ET
United Therapeutics Announces FDA Approval Of XPS(TM) And Steen Solution(TM) Used To Perform Centralized Ex-Vivo Lung Perfusion Services
2019-04-24 10:00 ET
United Therapeutics Corporation To Report First Quarter 2019 Financial Results Before The Market Opens On Wednesday, May 1, 2019
2019-04-18 02:52 ET
United Therapeutics Issues Statement In Response To Meritless Lawsuit
2019-04-08 10:00 ET
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
2019-03-12 10:00 ET
United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference

SEC forms

Show financial reports only

SEC form 8
2026-05-06 10:31 ET
United Therapeutics published news for 2026 q1
SEC form 8
2026-05-06 10:31 ET
United Therapeutics published news for 2026 q1
SEC form 10
2026-05-06 10:30 ET
United Therapeutics published news for 2026 q1
SEC form 8
2026-03-30 11:00 ET
United Therapeutics published news for 2025 q4
SEC form 8
2026-03-30 11:00 ET
United Therapeutics published news for 2025 q4
SEC form 8
2026-03-09 21:18 ET
United Therapeutics published news for 2025 q4
SEC form 8
2026-03-09 21:18 ET
United Therapeutics published news for 2025 q4
SEC form 8
2026-03-02 11:32 ET
United Therapeutics published news for 2025 q4
SEC form 8
2026-03-02 11:32 ET
United Therapeutics published news for 2025 q4
SEC form 8
2026-03-02 11:32 ET
United Therapeutics published news for 2025 q4
SEC form 8
2026-02-25 11:32 ET
United Therapeutics published news for 2025 q4
SEC form 8
2026-02-25 11:32 ET
United Therapeutics reported for 2025 q4
SEC form 10
2026-02-25 11:31 ET
United Therapeutics reported for 2025 q4
SEC form 8
2025-10-29 10:34 ET
United Therapeutics published news for 2025 q3
SEC form 8
2025-10-29 10:34 ET
United Therapeutics published news for 2025 q3
SEC form 10
2025-10-29 10:32 ET
United Therapeutics reported for 2025 q3
SEC form 8
2025-09-02 07:00 ET
United Therapeutics published news for 2025 q2
SEC form 8
2025-09-02 07:00 ET
United Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 10:36 ET
United Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 10:36 ET
United Therapeutics published news for 2025 q2
SEC form 10
2025-07-30 10:34 ET
United Therapeutics reported for 2025 q2
SEC form 10
2025-04-30 00:00 ET
United Therapeutics reported for 2025 q1
SEC form 8
2025-04-30 00:00 ET
United Therapeutics published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
United Therapeutics published news for 2025 q1
SEC form 10
2025-02-26 00:00 ET
United Therapeutics reported for 2024 q4
SEC form 8
2025-02-26 00:00 ET
United Therapeutics published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
United Therapeutics reported for 2024 q4
SEC form 8
2024-10-30 06:34 ET
United Therapeutics published news for 2024 q3
SEC form 8
2024-10-30 06:34 ET
United Therapeutics published news for 2024 q3
SEC form 10
2024-10-30 06:32 ET
United Therapeutics reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
United Therapeutics published news for 2024 q3
SEC form 8
2024-07-31 06:33 ET
United Therapeutics published news for 2024 q2
SEC form 8
2024-07-31 06:33 ET
United Therapeutics published news for 2024 q2
SEC form 10
2024-07-31 06:31 ET
United Therapeutics reported for 2024 q2
SEC form 10
2024-07-31 00:00 ET
United Therapeutics published news for 2024 q2
SEC form 8
2024-05-01 06:34 ET
United Therapeutics published news for 2024 q1
SEC form 8
2024-05-01 06:34 ET
United Therapeutics published news for 2024 q1
SEC form 10
2024-05-01 06:32 ET
United Therapeutics reported for 2024 q1
SEC form 10
2024-05-01 00:00 ET
United Therapeutics published news for 2024 q1
SEC form 8
2024-02-21 06:05 ET
United Therapeutics published news for 2023 q4
SEC form 8
2024-02-21 06:05 ET
United Therapeutics reported for 2023 q4
SEC form 8
2024-02-21 06:05 ET
United Therapeutics published news for 2023 q4
SEC form 10
2024-02-21 06:03 ET
United Therapeutics reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
United Therapeutics published news for 2023 q4
SEC form 8
2023-11-01 06:05 ET
United Therapeutics published news for 2023 q3
SEC form 10
2023-11-01 06:03 ET
United Therapeutics reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
United Therapeutics published news for 2023 q3
SEC form 6
2023-08-02 06:05 ET
United Therapeutics published news for 2023 q2
SEC form 10
2023-08-02 06:02 ET
United Therapeutics reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
United Therapeutics published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-07-24 16:30 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-07-14 16:31 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-06-28 06:47 ET
United Therapeutics published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
United Therapeutics published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
United Therapeutics published news for 2023 q1
SEC form 6
2023-03-31 16:30 ET
United Therapeutics published news for 2022 q4
SEC form 6
2023-02-22 06:06 ET
United Therapeutics published news for 2022 q4
SEC form 10
2023-02-22 06:03 ET
United Therapeutics reported for 2022 q4
SEC form 10
2023-02-22 00:00 ET
United Therapeutics reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
United Therapeutics reported for 2022 q4
SEC form 6
2023-01-09 06:03 ET
United Therapeutics published news for 2022 q4
SEC form 6
2022-11-02 06:05 ET
United Therapeutics published news for 2022 q3
SEC form 10
2022-11-02 06:03 ET
United Therapeutics reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
United Therapeutics reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
United Therapeutics reported for 2022 q3
SEC form 6
2022-10-11 07:15 ET
United Therapeutics published news for 2022 q3
SEC form 6
2022-09-20 06:00 ET
United Therapeutics published news for 2022 q2
SEC form 6
2022-09-01 06:01 ET
United Therapeutics published news for 2022 q2
SEC form 6
2022-08-03 06:06 ET
United Therapeutics published news for 2022 q2
SEC form 10
2022-08-03 06:03 ET
United Therapeutics reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
United Therapeutics reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
United Therapeutics reported for 2022 q2
SEC form 6
2022-06-28 17:08 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-05-24 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-05-04 06:08 ET
United Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 06:04 ET
United Therapeutics reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
United Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
United Therapeutics reported for 2022 q1
SEC form 6
2022-04-29 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-04-22 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-04-01 06:13 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-02-24 06:09 ET
United Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 06:05 ET
United Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
United Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
United Therapeutics published news for 2021 q4
SEC form 6
2022-01-18 06:01 ET
United Therapeutics published news for 2021 q4
SEC form 6
2021-12-27 06:02 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-11-03 06:07 ET
United Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 06:03 ET
United Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
United Therapeutics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-10-18 06:01 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-10-01 06:01 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-08-19 06:00 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 06:13 ET
United Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 06:04 ET
United Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
United Therapeutics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-07-14 06:15 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-06-25 16:30 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-23 06:01 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-16 06:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-07 06:01 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-03 06:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 06:17 ET
United Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 06:10 ET
United Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
United Therapeutics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-29 06:06 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-19 06:02 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-01 06:03 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-03-03 06:02 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 06:09 ET
United Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 06:07 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-10 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-05 06:05 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-28 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-22 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 17:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2020-12-28 06:08 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-12-09 06:00 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-12-02 06:01 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-10-28 06:21 ET
United Therapeutics published news for 2020 q3
SEC form 10
2020-10-28 06:12 ET
United Therapeutics published news for 2020 q3